How S 1836 changes current law

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill increases the number of negotiation-eligible drugs and modifies related definitions and price ceilings in the Drug Price Negotiation Program.

• 42 U.S.C. 1320f-1(a)

  2028, 15 negotiation-eligible drugs → 2028 or a subsequent year, 50 negotiation-eligible drugs

  Increases the maximum number of drugs eligible for negotiation from 15 to 50 starting in 2028.

• 42 U.S.C. 1320f-1(a)

  ; and → .

  Closes the list of drug negotiation criteria by removing a conjunction.

• 42 U.S.C. 1320f-1(a)

  paragraph (4)

  Removes a section of the statute that likely detailed additional negotiation criteria for eligible drugs.

• 42 U.S.C. 1320f-1(e)(1)

  7 years → 3 years

  Reduces the exclusive period for qualifying single source drugs from 7 years to 3 years.

• 42 U.S.C. 1320f-1(e)(1)

  11 years → 3 years

  Reduces the window for additional qualifying criteria from 11 years to 3 years.

• 42 U.S.C. 1320f-3(c)(3)

  75 percent → 76 percent

  Increases the ceiling for the maximum fair price from 75% to 76%.

• 42 U.S.C. 1320f-3(c)(3)

  65 percent → 55 percent

  Decreases the second tier ceiling for the maximum fair price from 65% to 55%.

• 42 U.S.C. 1320f-3(c)(3)

  40 percent → 30 percent

  Decreases the third tier ceiling for the maximum fair price from 40% to 30%.

• The amendments made by this section shall apply with respect to initial price applicability years beginning with initial price applicability year 2028.

  Establishes that the new amendments will take effect starting with the price applicability year of 2028.